Veracyte Inc (VCYT) Stock Analysis

Veracyte Inc (VCYT) is a publicly traded company in the HEALTHCARE sector. It trades at $56.97, carries a market capitalization of $4.73B, a price-to-earnings ratio of 52.02. This page summarizes the public market data, fundamentals, and frequently asked questions for VCYT, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - DIAGNOSTICS & RESEARCH

Exchange: NASDAQ

Key Metrics

Price: $56.97
Market Cap: $4.73B
P/E Ratio: 52.02
EPS: $1.14
52-Week High: $60.91
52-Week Low: $22.61

Market Sentiment

Veracyte Inc currently has a Neutral sentiment score of -0.02.

About Veracyte Inc

Veracyte, Inc. is a genomic diagnostics company in the United States and internationally. The company is headquartered in South San Francisco, California.

GNG Research Analysis

GNG Research scores Veracyte Inc (VCYT) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for VCYT.

Frequently Asked Questions

Does VCYT pay dividends?

Veracyte Inc (VCYT) does not currently pay a regular dividend.

What is VCYT's P/E ratio?

Veracyte Inc has a price-to-earnings (P/E) ratio of 52.02.

What is VCYT's market cap?

Veracyte Inc (VCYT) has a market capitalization of $4.73B with a current stock price of $56.97.